Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Berruti

Showing results (31-40 of 150) with videos related to

Pageof 15
Sort By:
Tumori|December 31, 1990
Prevention of nausea and vomiting in cisplatin-treated patients by a selective 5-hydroxytryptamine (5-HT3) receptor antagonist, ICS 205-930L Dogliotti, R Faggiuolo, A Berruti, et al.
Anticancer Research|January 18, 2003
Gemcitabine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a phase II studyS Bretti, E Manzin, C Loddo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 1994
Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancerF Orlandi, P Caraci, A Berruti, et al.
American Journal of Clinical Oncology|February 1, 1995
Combination chemotherapy with carboplatin and methotrexate in the treatment of advanced urothelial carcinoma. A phase II studyL Dogliotti, O Bertetto, A Berruti, et al.
Journal of Endocrinological Investigation|January 25, 2014
Management of adrenal cancer: a 2013 updateM Terzolo, F Daffara, A Ardito, et al.
The Prostate|December 16, 1997
Pamidronate administration improves the secondary hyperparathyroidism due to "Bone Hunger Syndrome" in a patient with osteoblastic metastases from prostate cancerA Berruti, P Sperone, G Fasolis, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 27, 2019
Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanomaF Consoli, M Bersanelli, G Perego, et al.
Tumori|October 31, 1992
Favorable response of metastatic adrenocortical carcinoma to etoposide, adriamycin and cisplatin (EAP) chemotherapy. Report of two casesA Berruti, M Terzolo, P Paccotti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 29, 2006
Management of the side-effects of intravenous bisphosphonates: targeting the serum parathyroid hormone elevationA Berruti, M Tucci, D Generali, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 1995
Feasibility of the association of mitotane with etoposide, adriamycin and cisplatin combination chemotherapy in advanced adrenocortical cancer patients. Report on 7 casesA Pia, A Berruti, M Terzolo, et al.
Pageof 15

Showing results (31-40 of 150) with videos related to

Sort By:
Pageof 15
Tumori|December 31, 1990
Prevention of nausea and vomiting in cisplatin-treated patients by a selective 5-hydroxytryptamine (5-HT3) receptor antagonist, ICS 205-930L Dogliotti, R Faggiuolo, A Berruti, et al.
Anticancer Research|January 18, 2003
Gemcitabine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a phase II studyS Bretti, E Manzin, C Loddo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 1994
Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancerF Orlandi, P Caraci, A Berruti, et al.
American Journal of Clinical Oncology|February 1, 1995
Combination chemotherapy with carboplatin and methotrexate in the treatment of advanced urothelial carcinoma. A phase II studyL Dogliotti, O Bertetto, A Berruti, et al.
Journal of Endocrinological Investigation|January 25, 2014
Management of adrenal cancer: a 2013 updateM Terzolo, F Daffara, A Ardito, et al.
The Prostate|December 16, 1997
Pamidronate administration improves the secondary hyperparathyroidism due to "Bone Hunger Syndrome" in a patient with osteoblastic metastases from prostate cancerA Berruti, P Sperone, G Fasolis, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 27, 2019
Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanomaF Consoli, M Bersanelli, G Perego, et al.
Tumori|October 31, 1992
Favorable response of metastatic adrenocortical carcinoma to etoposide, adriamycin and cisplatin (EAP) chemotherapy. Report of two casesA Berruti, M Terzolo, P Paccotti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 29, 2006
Management of the side-effects of intravenous bisphosphonates: targeting the serum parathyroid hormone elevationA Berruti, M Tucci, D Generali, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 1995
Feasibility of the association of mitotane with etoposide, adriamycin and cisplatin combination chemotherapy in advanced adrenocortical cancer patients. Report on 7 casesA Pia, A Berruti, M Terzolo, et al.
Pageof 15